000			05902cam a2200649Ia 4500
001			ocn784885298
003			OCoLC
005			20171224113920.0
006			m o d
007			cr |n|---|||||
008			120409s2012 njua ob 001 0 eng d
040			_aEBLCP _beng _epn _cEBLCP _dOCLCQ _dMHW _dDG1 _dYDXCP _dMYG _dOCLCQ _dHEBIS _dOCLCF _dOCLCA _dOCLCQ _dS3O _dOCLCQ _dDEBBG
020			_a9783527632909 _q(electronic bk.)
020			_a3527632905 _q(electronic bk.)
020			_z9783527651252
020			_z352765125X
029	1		_aAU@ _b000049569125
029	1		_aNZ1 _b15900693
029	1		_aDEBBG _bBV043394438
035			_a(OCoLC)784885298
050		4	_aRS380 _b.P488 2012eb
082	0	4	_a615.1 _223
049			_aMAIN
245	0	0	_aPharmaceutical biotechnology : _bdrug discovery and clinical applications.
250			_a2nd rev. ed. / _bedited by Oliver Kayser, Heribert Warzecha.
260			_aHoboken : _bJohn Wiley & Sons, _c2012.
300			_a1 online resource (xxvii, 647 pages) : _billustrations
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
500			_aPrevious edition: 2004.
504			_aIncludes bibliographical references and index.
505	0		_aCover; Related Titles; Title page; Copyright page; Preface to the 2nd Edition; List of Contributors; Part One: Concepts and Methods for Recombinant Drug Production; 1 Pharmaceutical Biotechnology and Industrial Applications -- Learning Lessons from Molecular Biology; 1.1 Introduction; 1.2 Research Developments; 1.3 Production Hosts and Upstream/Downstream Processing; 1.4 Future Outlook; 2 Prokaryotic Cells in Biotech Production; 2.1 Introduction; 2.2 Production of Natural Products by Microorganisms; 2.3 Prokaryotes as Producers of Recombinant Therapeutic Proteins.
505	8		_a3 Mammalian Cells in Biotech Production3.1 Introduction; 3.2 Process Concepts and Cells; 3.3 CHO-Derived Production Cell Lines; 3.4 Rapid Generation of High-Producing Cell Lines; 3.5 Silencing -- Stability of Expression; 3.6 High-Throughput Bioprocess Development; 3.7 Disposable Bioreactors; 3.8 Transient Gene Expression (TGE); 3.9 Conclusions; 4 Biopharmaceuticals from Plants; 4.1 Introduction; 4.2 Basics in Plant Biotechnology; 4.3 Plant Cell Cultures as Production System for Human Glucocerebrosidase; 4.4 Insulin from Safflower -- A Unique Purification Scheme.
505	8		_a4.5 Fast and Scalable Transient Tobacco-Based Expression Systems4.6 Conclusion; 5 Production of Biopharmaceuticals in Transgenic Animals; 5.1 Introduction; 5.2 Sites of Production; 5.3 Transgenic Constructs; 5.4 Methods for the Production of Transgenic Animals; 5.5 Analysis of Transgenic Animals; 5.6 Quality and Safety of the Product; 5.7 Conclusions and Outlook; 6 Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application -- and Back Again; 6.1 Drug Discovery and Development; 6.2 The Nature of Models and the Need for Them.
505	8		_a6.3 New Technologies Toolbox6.4 Strategic Use of the New Technology Tools; 6.5 Translation as a Two-Way Process; 6.6 Concluding Comment; Part Two: Bringing the Drug into Action -- From Downstreaming to Approval; 7 Overview and Classification of Approved Recombinant Drugs; 7.1 Introduction; 7.2 Classification of Recombinant Drugs from a Technical Point of View; 7.3 Expression Systems; 7.4 Proteins Derived from Modified Genes; 7.5 Artificial Proteins; 7.6 Post-expression Modifications of Recombinant Proteins; 7.7 Biosimilars; 8 Downstream Processing; 8.1 Introduction.
505	8		_a8.2 General Principles of DSP8.3 Clarification; 8.4 Chromatography; 8.5 Ultrafiltration/Diafiltration, and Virus Filtration; 8.6 Crystallization; 8.7 Recent Developments in Downstream Processing; 9 Characterization of Recombinant Proteins; 9.1 Introduction; 9.2 Physical Chemical Characterization; 9.3 Biological Characterization of Biopharmaceuticals In Vitro; Acknowledgments; Legals; 10 Formulation Strategies for Recombinant Protein and Related Biotech Drugs; 10.1 Introduction; 10.2 Formulation and Stability of Protein Solutions; 10.3 Formulation of Vaccines.
505	8		_a11 Drug Approval in the European Union and United States.
520			_a"This second edition of a very successful book is thoroughly updated with existing chapters completely rewritten while the content has more than doubled from 16 to 36 chapters. As with the first edition, the focus is on industrial pharmaceutical research, written by a team of industry experts from around the world, while quality and safety management, drug approval and regulation, patenting issues, and biotechnology fundamentals are also covered. In addition, this new edition now not only includes biotech drug development but also the use of biopharmaceuticals in diagnostics and vaccinations."--Provided by publisher.
588	0		_aPrint version record.
650		0	_aPharmaceutical biotechnology.
650		7	_aPharmaceutical biotechnology. _2fast _0(OCoLC)fst01060106
650		7	_aPharmazeutische Technologie _2gnd _0(DE-588)4045699-7
650		7	_aBiotechnologie _2gnd _0(DE-588)4069491-4
650		7	_aBioteknik. _2sao
655		4	_aElectronic books.
700	1		_aKayser, Oliver.
700	1		_aWarzecha, Heribert.
710	2		_aWiley InterScience (Online service)
776	0	8	_iPrint version: _aKayser, Oliver. _tPharmaceutical Biotechnology : Drug Discovery and Clinical Applications. _dHoboken : John Wiley & Sons, ©2012 _z9783527329946 _w(OCoLC)794134901
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527632909 _zWiley Online Library
938			_aEBL - Ebook Library _bEBLB _nEBL875950
938			_aYBP Library Services _bYANK _n7607353
938			_aYBP Library Services _bYANK _n7644123
938			_aYBP Library Services _bYANK _n7585093
994			_a92 _bDG1
999			_c11818 _d11818